NCT06470971View on ClinicalTrials.gov

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients with Advanced Cancer, CIRES Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Advanced Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm
Interventions
BIOLOGICAL

Anti-PD-L1 Monoclonal Antibody

Receive anti-PD-L1 monoclonal antibody therapy

BIOLOGICAL

Anti-PD1 Monoclonal Antibody

Receive anti-PD1 monoclonal antibody therapy

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Siltuximab

Given IV

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Yuanquan Yang

OTHER